MedTrace Logo

An Examination of Cognitive Fatigue Using Functional Neuroimaging

NCT04885894 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-03-01

No results posted yet for this study

Summary

The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS). Cognitive fatigue is the kind of fatigue that occurs after intense mental concentration as after a session of problem solving.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

Zeposia

Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • Hackensack Meridian Health

    collaborator OTHER

  • St. Barnabas Medical Center

    collaborator OTHER

  • Kessler Foundation

    lead OTHER

Principal Investigators

  • John DeLuca, PhD · Kessler Foundation

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04885894 on ClinicalTrials.gov